Research programme: antibody-inducing peptides - FunPep/Osaka University School of Medicine
Alternative Names: antibody-derived peptidesLatest Information Update: 28 Jul 2023
At a glance
- Originator FunPep; Osaka University School of Medicine
- Developer FunPep; Kagawa University; Kyoto Prefectural University of Medicine; MEDIPAL HOLDINGS CORPORATION; Osaka University School of Medicine; Shionogi; Sumitomo Pharma
- Class Analgesics; Antiallergics; Antihypertensives; Antineoplastics; Antithrombotics; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Familial adenomatous polyposis; Hypersensitivity; Hypertension; Neurological disorders; Pain; Psoriasis; Thrombosis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Allergy in Japan (Parenteral)
- 28 Jul 2023 No recent reports of development identified for research development in Familial-adenomatous-polyposis in Japan (Parenteral)
- 28 Jul 2023 No recent reports of development identified for research development in Hypertension in Japan (Parenteral)